Yuankai SHI
Aerospace Center Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yuankai SHI as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07806500 · Phase Ib Study of Oral R01 Monotherapy in Advanced Solid TumorsBeijing Anjianxi Bio-Medical Technology Co., Ltd. · not yet recruiting · Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer · principal investigator
- Ph2NCT06886139 · A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.Zhejiang Teruisi Pharmaceutical Inc. · not yet recruiting · CD20-positive Diffuse Large B-Cell Lymphoma · principal investigator
- Ph3NCT06792253 · Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBeBetter Med Inc · recruiting · Relapsed/Refractory Diffuse Large B-Cell Lymphoma · principal investigator
- Ph3NCT06759857 · FHND9041 Versus Afatinib for Non-small Cell Lung CancerJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · enrolling by invitation · Non Small Cell Lung Cancer · principal investigator
- Ph3NCT06658353 · Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsJiangsu vcare pharmaceutical technology co., LTD · recruiting · Locally Advanced Solid Tumor · principal investigator
- Ph1NCT06565689 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012Excyte Biopharma Ltd · recruiting · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT06410092 · Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001Sound Biopharmaceuticals Ltd. · recruiting · Solid Tumor · principal investigator
- Ph4NCT06285370 · A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic TherapyKyowa Kirin China Pharmaceutical Co., Ltd. · completed · Cutaneous T-Cell Lymphoma · principal investigator
- Ph2NCT06173037 · RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerRemeGen Co., Ltd. · completed · Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer · principal investigator
- Ph1NCT06164327 · Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBeBetter Med Inc · unknown · Relapsed/Refractory Diffuse Large B-Cell Lymphoma · principal investigator
- Ph3NCT06128837 · Study of LY01610 in Patients With Recurrent Small Cell Lung CancerLuye Pharma Group Ltd. · recruiting · Relapsed Small Cell Lung Cancer · principal investigator
- Ph2NCT06074107 · Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma SubjectsBeBetter Med Inc · completed · Relapsed or Refractory Diffuse Large B-cell Lymphoma · principal investigator
- Ph2NCT05948813 · TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesTYK Medicines, Inc · recruiting · NSCLC, EGFR Activating Mutation, Brain Metastases · principal investigator
- Ph2NCT05900219 · Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyShanghai Kechow Pharma, Inc. · unknown · Non-small-cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05434299 · A Study of TFX05-01 in Patients With Advanced Solid TumorsZhejiang Yangli Pharmaceutical Technology Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph1NCT05395533 · A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.Zhejiang Teruisi Pharmaceutical Inc. · active not recruiting · CD20-positive B-cell Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT05341557 · A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory LymphomaBetta Pharmaceuticals Co., Ltd. · recruiting · Advanced Solid Tumor, Lymphoma, NSCLC · principal investigator
- Ph3NCT05318443 · A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerShanghai Institute Of Biological Products · completed · Non-squamous Non-small-cell Lung Cancer · principal investigator
- Ph4NCT05219162 · Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).AstraZeneca · completed · Advanced NSCLC · principal investigator
- Ph1/Ph2NCT05189093 · Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory LymphomaHangzhou Hanx Biopharmaceuticals, Ltd. · completed · Relapsed/Refractory Lymphoma · principal investigator
- Ph2NCT05146219 · Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationTYK Medicines, Inc · completed · NSCLC, EGFR Activating Mutation, Brain Metastases · principal investigator
- Ph2NCT04999800 · Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Shi Yuankai · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1/Ph2NCT04996121 · A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid TumorsXuanzhu Biopharmaceutical Co., Ltd. · recruiting · Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04994626 · Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesChinese Academy of Medical Sciences · unknown · DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation · principal investigator
- Ph1NCT04977167 · Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or LymphomaHitGen Inc. · completed · Solid Tumor, Lymphoma · principal investigator
- Ph2/Ph3NCT04874844 · JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and SafetyBeijing Dongfang Biotech Co., Ltd. · unknown · NSCLC · study chair
- Ph2NCT04857164 · Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in ChinaYuankai Shi · recruiting · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT04838548 · A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung CancerLepu Biopharma Co., Ltd. · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph3NCT04830813 · Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerChipscreen Biosciences, Ltd. · completed · Small Cell Lung Cancer · principal investigator
- N/ANCT04740996 · Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in ChinaShi Yuankai · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT04671303 · To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · completed · Lung Cancer · principal investigator
- Ph1NCT04622072 · XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung CancerSihuan Pharmaceutical Holdings Group Ltd. · terminated · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04620837 · Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyChinese Academy of Medical Sciences · unknown · Small Cell Lung Carcinoma · principal investigator
- Ph1NCT04617314 · A Study of RC108-ADC in Subjects With Advanced Malignant Solid TumorsRemeGen Co., Ltd. · completed · Solid Tumor · principal investigator
- Ph1/Ph2NCT04614740 · The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid TumorsJiangsu vcare pharmaceutical technology co., LTD · unknown · Locally Advanced Solid Tumor, Metastatic Solid Tumor · principal investigator
- Ph2NCT04600947 · Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTaizhou HoudeAoke Biomedical Co., Ltd. · unknown · Primary Mediastinal Large B-Cell Lymphoma (PMBCL) · principal investigator
- Ph2NCT04518137 · A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)Shanghai Antengene Corporation Limited · terminated · Advanced Solid Tumors · principal investigator
- N/ANCT04491721 · Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCLChinese Academy of Medical Sciences · enrolling by invitation · Diffuse Large B Cell Lymphoma · principal investigator
- Ph3NCT04416035 · A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLCZhejiang Teruisi Pharmaceutical Inc. · unknown · Advanced Non-squamous Non-small-cell Lung Cancer · principal investigator
- Ph2NCT04381910 · Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung CancerLuye Pharma Group Ltd. · completed · Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT04304040 · A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaBeijing InnoCare Pharma Tech Co., Ltd. · unknown · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory · principal investigator
- Ph2NCT04146181 · Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph3NCT04146402 · SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT04121286 · A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaAllist Pharmaceuticals, Inc. · completed · Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma · principal investigator
- Ph1/Ph2NCT04110301 · MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)Beijing Mabworks Biotech Co., Ltd. · unknown · Follicular Lymphoma and Marginal Zone Lymphoma · principal investigator
- Ph1NCT04103905 · A Study of MIL62 in Treatment of CD20 Positive B-cell LymphomasBeijing Mabworks Biotech Co., Ltd. · completed · CD20-positive B Cell Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT04093466 · A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid TumorsBeijing Konruns Pharmaceutical Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph2NCT04093115 · Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell CarcinomaBeijing Konruns Pharmaceutical Co., Ltd. · withdrawn · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT04058587 · A Phase I Trial of Simmitinib in Advanced Solid TumorsCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph2NCT04023916 · Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Chinese Academy of Medical Sciences · unknown · Diffuse Large B-Cell Lymphoma, Sintilimab, TP53 Mutation · principal investigator
- Ph1/Ph2NCT04024696 · A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese PatientsXynomic Pharmaceuticals, Inc. · active not recruiting · Non Hodgkin Lymphoma · principal investigator
- Ph2NCT03936153 · Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Xynomic Pharmaceuticals, Inc. · recruiting · Diffuse Large B-cell Lymphoma (DLBCL) · principal investigator
- Ph2NCT03934567 · A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaXynomic Pharmaceuticals, Inc. · active not recruiting · Lymphoma, Follicular · principal investigator
- Ph2NCT03904719 · CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)AnewPharma · unknown · Small Cell Lung Cancer · study chair
- Ph2NCT03874741 · SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph3NCT03866499 · A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer PatientsBeta Pharma Shanghai · unknown · NSCLC · principal investigator
- Ph2NCT03812809 · A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation PositiveBeta Pharma Shanghai · completed · NSCLC · principal investigator
- Ph1/Ph2NCT03751592 · Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung CancerSichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd · unknown · Advanced Lung Cancer · principal investigator
- Ph2NCT03744208 · SCT200 Injection in Patients With Head and Neck Squamous Cell CarcinomaShi Yuankai · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT03731390 · GR1405 Injection in Patients With Advanced Solid Tumor or LymphomaChinese Academy of Medical Sciences · unknown · Tumor, Solid, Lymphoma · principal investigator
- Ph2NCT03713372 · Safety and Efficacy of SCT200 in Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Cancer · principal investigator
- Ph2NCT03693547 · Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)Beijing Biostar Pharmaceuticals Co., Ltd. · completed · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03639181 · Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Genor Biopharma Co., Ltd. · unknown · B-cell Non-Hodgkin's Lymphoma · principal investigator
- Ph1/Ph2NCT03639467 · Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal CarcinomaChinese Academy of Medical Sciences · unknown · Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma · principal investigator
- Ph2NCT03623581 · Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)Genor Biopharma Co., Ltd. · unknown · Alveolar Soft Part Sarcoma · principal investigator
- Ph1/Ph2NCT03565003 · A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in ChinaJacobio Pharmaceuticals Co., Ltd. · completed · Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer · study chair
- Ph2NCT03502629 · Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Genor Biopharma Co., Ltd. · unknown · Peripheral T Cell Lymphoma · principal investigator
- Ph1/Ph2NCT03420079 · A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive MutationAhon Pharmaceutical Co., Ltd. · unknown · Lung Cancer · principal investigator
- N/ANCT03412344 · Factors Influencing Cancer Patients Participation in Clinical Trials in China.Chinese Academy of Medical Sciences · unknown · Cancer · principal investigator
- Ph2NCT03410004 · Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaChinese Academy of Medical Sciences · unknown · Experimental · principal investigator
- Ph2NCT03405272 · Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRCSinocelltech Ltd. · unknown · Metastatic Colorectal Cancer · principal investigator
- Ph1/Ph2NCT03389815 · A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsQilu Pharmaceutical Co., Ltd. · unknown · Advanced Solid Tumor, Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT03386955 · BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung CancerBeta Pharma Shanghai · completed · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03374007 · Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/LymphomaGenor Biopharma Co., Ltd. · unknown · Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma · principal investigator
- Ph3NCT03206151 · CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal CancerTaizhou Mabtech Pharmaceutical Co.,Ltd · completed · Metastatic Colorectal Cancer · principal investigator
- Ph3NCT03150875 · A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLCInnovent Biologics (Suzhou) Co. Ltd. · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT03117335 · Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerJiangsu Wuzhong Pharmaceutical Group Co., Ltd. · completed · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph3NCT03083743 · A Phase III Trial of Recombinant Human Apo-2 Ligand for InjectionShanghai Gebaide Biotechnology Co., Ltd. · unknown · Non-small-cell Lung Cancer (NSCLC) Stage IV · principal investigator
- Ph3NCT03058094 · A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIHangzhou ACEA Pharmaceutical Research Co., Ltd. · withdrawn · NSCLC · principal investigator
- Ph1/Ph2NCT02981745 · Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCentaurus Biopharma Co., Ltd. · unknown · Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia · principal investigator
- Ph1NCT02916095 · Kanitinib in Treating Patients With Advanced Solid TumorsBeijing Konruns Pharmaceutical Co., Ltd. · completed · Solid Tumors · principal investigator
- Ph1NCT02914990 · Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsBetta Pharmaceuticals Co., Ltd. · completed · Non-Small Cell Lung Cancer · study chair
- Ph1NCT02836834 · Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsShanghai Junshi Bioscience Co., Ltd. · unknown · Lymphoma, Lung Cancer · principal investigator
- Ph2NCT02815007 · Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerYuankai Shi · unknown · Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT02809573 · Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsChipscreen Biosciences, Ltd. · completed · Peripheral T-cell Lymphoma · principal investigator
- Ph1NCT02695550 · Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung CancerCentaurus Biopharma Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT02503150 · Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal CancerSecond Military Medical University · unknown · Metastatic Colorectal Cancer · principal investigator
- Ph1NCT02478866 · Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid TumorsBetta Pharmaceuticals Co., Ltd. · completed · Solid Tumors · study chair
- Ph2NCT02323737 · Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung CancerChinese Academy of Medical Sciences · completed · Extensive-stage Small Cell Lung Cancer · principal investigator
- Ph1NCT02136342 · Phase 1 Trial of Chlorogenic Acid in Patients With Advanced CancerChinese Academy of Medical Sciences · terminated · Advanced Cancer · principal investigator
- Ph1NCT02131688 · Phase I Study of Mitoxantrone Hydrochloride Liposome InjectionCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Malignant Lymphoma · principal investigator
- Ph1NCT02122809 · Phase I Study of Chiauranib in Patients With Advanced Solid TumorsChipscreen Biosciences, Ltd. · completed · Solid Tumors · principal investigator
- Ph1NCT02066870 · Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT02043756 · Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome InjectionCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · completed · Neoplasms · principal investigator
- Ph2NCT02005458 · Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving ChemotherapyXiamen Amoytop Biotech Co., Ltd. · completed · Non Small Cell Lung Cancer, Breast Cancer · principal investigator
- Ph2NCT01918241 · Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced NeutropeniaHangzhou Jiuyuan Gene Engineering Co. Ltd., · unknown · Neutropenia · principal investigator
- Ph2NCT01836679 · Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung CancerChipscreen Biosciences, Ltd. · completed · Non-small-cell Lung Cancer · principal investigator
- Ph1NCT01772732 · Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLCJiangsu Simcere Pharmaceutical Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2/Ph3NCT01550055 · Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal CancerShanghai Zhangjiang Biotechnology Limited Company · completed · Metastatic Colorectal Cancer · study chair
- Ph3NCT01459887 · Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's LymphomaShanghai CP Guojian Pharmaceutical Co., Ltd. · completed · Diffuse Large B Cell Lymphoma · principal investigator
- Ph2NCT01439191 · Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast CancerShanghai CP Guojian Pharmaceutical Co., Ltd. · completed · Metastatic Breast Cancer · study director
- Ph3NCT01285219 · A Study Comparing Pegylated Filgrastim and Filgrastim in Support for ChemotherapyChinese Academy of Medical Sciences · completed · Cancer · principal investigator
- Ph2NCT01024712 · Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Lung Cancer · principal investigator
- Ph1NCT00985998 · Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung CancerBiotech Pharmaceutical Co., Ltd. · withdrawn · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:38 UTC. The ranking covers the 200 most relevant of 905 PubMed records, and a shared surname and initials can bring in a namesake. All 905 on PubMed
- 1,719 citationsRCR 75.1
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.Cancer Discov · 20201,183 citationsRCR 55.1
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.N Engl J Med · 2015675 citationsRCR 25.2
- 593 citationsRCR 30.9
- 561 citationsRCR 18.1
- Transfer of Fresh versus Frozen Embryos in Ovulatory Women.N Engl J Med · 2018427 citationsRCR 25.3
- Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial.Lancet · 2019395 citationsRCR 25.3
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2021381 citationsRCR 18.5
- 356 citationsRCR 18.6
- Live Birth with or without Preimplantation Genetic Testing for Aneuploidy.N Engl J Med · 2021280 citationsRCR 21.8